AR091647A1 - Purificacion de iduronato-2-sulfatasa - Google Patents

Purificacion de iduronato-2-sulfatasa

Info

Publication number
AR091647A1
AR091647A1 ARP130102350A AR091647A1 AR 091647 A1 AR091647 A1 AR 091647A1 AR P130102350 A ARP130102350 A AR P130102350A AR 091647 A1 AR091647 A1 AR 091647A1
Authority
AR
Argentina
Prior art keywords
purified recombinant
sulfatase
chromatography
iduronate
hcp
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR091647(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of AR091647A1 publication Critical patent/AR091647A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ARP130102350 2012-06-29 2013-07-01 Purificacion de iduronato-2-sulfatasa AR091647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
AR091647A1 true AR091647A1 (es) 2015-02-18

Family

ID=49778401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102350 AR091647A1 (es) 2012-06-29 2013-07-01 Purificacion de iduronato-2-sulfatasa

Country Status (39)

Country Link
US (7) US9051556B2 (enExample)
EP (2) EP2867245B1 (enExample)
JP (4) JP6171007B2 (enExample)
KR (5) KR101380740B1 (enExample)
CN (3) CN107596357A (enExample)
AR (1) AR091647A1 (enExample)
AU (3) AU2013282395C1 (enExample)
BR (1) BR112014032567B1 (enExample)
CA (2) CA3008945A1 (enExample)
CL (1) CL2014003567A1 (enExample)
CO (1) CO7240396A2 (enExample)
CR (1) CR20140588A (enExample)
CY (1) CY1121519T1 (enExample)
DK (1) DK2867245T3 (enExample)
DO (1) DOP2014000294A (enExample)
EA (2) EA034549B1 (enExample)
ES (1) ES2689468T3 (enExample)
GT (1) GT201400303A (enExample)
HK (3) HK1209431A1 (enExample)
HR (1) HRP20181897T1 (enExample)
HU (1) HUE040769T2 (enExample)
IL (4) IL236315A (enExample)
LT (1) LT2867245T (enExample)
MX (3) MX366906B (enExample)
MY (3) MY192068A (enExample)
NZ (3) NZ743910A (enExample)
PE (1) PE20150720A1 (enExample)
PH (3) PH12014502871A1 (enExample)
PL (1) PL2867245T3 (enExample)
PT (1) PT2867245T (enExample)
RS (1) RS58005B1 (enExample)
SG (2) SG11201408761VA (enExample)
SI (1) SI2867245T1 (enExample)
SM (1) SMT201800612T1 (enExample)
TR (1) TR201815811T4 (enExample)
TW (2) TWI587869B (enExample)
UA (2) UA121959C2 (enExample)
WO (1) WO2014005014A2 (enExample)
ZA (2) ZA201409397B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
PL2485761T3 (pl) 2009-10-09 2019-10-31 Armagen Inc Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
WO2018038243A1 (ja) 2016-08-25 2018-03-01 Ｊｃｒファーマ株式会社 抗体融合蛋白質の製造方法
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
JP2021500857A (ja) 2017-10-02 2021-01-14 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 酵素補充療法用酵素を含む融合タンパク質
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3898689A1 (en) * 2018-12-20 2021-10-27 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
EP3917951A1 (en) * 2019-01-30 2021-12-08 Amgen, Inc Aflibercept attributes and methods of characterizing and modifying thereof
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2022087229A1 (en) * 2020-10-23 2022-04-28 Alexion Pharmaceuticals, Inc. Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
EP0750511B1 (en) 1994-03-16 2003-06-11 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
IL145893A0 (en) 1999-04-26 2002-07-25 Genentech Inc Cell culture process for glycoproteins
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
CA2383800A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
CA2400034A1 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
JP2003527851A (ja) 2000-03-17 2003-09-24 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ７つのヒト卵巣および卵巣癌関連タンパク質
WO2001079444A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
KR100788093B1 (ko) 2002-04-26 2007-12-21 제넨테크, 인크. 단백질의 비친화성 정제
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
PL377731A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
CN101444621B (zh) 2003-02-11 2013-11-20 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ES2370417T3 (es) 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
SI3219795T1 (sl) * 2008-01-18 2024-10-30 Biomarin Pharmaceutical Inc. Izdelava akitvnih visoko fosforiliranih humanih encimov lizomske sulfataze in njihova uporaba
PL2485761T3 (pl) 2009-10-09 2019-10-31 Armagen Inc Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
JPWO2011108451A1 (ja) * 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
JP6063380B2 (ja) * 2010-06-25 2017-01-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド サンフィリポ症候群ｂ型の処置
ES2754234T3 (es) 2010-06-25 2020-04-16 Shire Human Genetic Therapies Métodos y composiciones para la administración SNC de iduronato-2-sulfatasa
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012042857A1 (ja) 2010-09-28 2012-04-05 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
MY157087A (en) 2016-04-19
TWI553120B (zh) 2016-10-11
UA121959C2 (uk) 2020-08-25
CL2014003567A1 (es) 2015-04-24
HK1209767A1 (en) 2016-04-08
MY192068A (en) 2022-07-25
PH12014502871B1 (en) 2015-02-23
DK2867245T3 (en) 2018-11-26
US12359178B2 (en) 2025-07-15
HUE040769T2 (hu) 2019-03-28
ZA201803289B (en) 2021-04-28
GT201400303A (es) 2017-08-31
ES2689468T3 (es) 2018-11-14
AU2016200469A1 (en) 2016-02-18
TW201410868A (zh) 2014-03-16
RS58005B1 (sr) 2019-02-28
JP2018121645A (ja) 2018-08-09
SG10201703489VA (en) 2017-05-30
US20240043817A1 (en) 2024-02-08
LT2867245T (lt) 2018-11-12
CA2877517C (en) 2018-07-31
CN104583225A (zh) 2015-04-29
WO2014005014A3 (en) 2014-02-27
US20240401010A1 (en) 2024-12-05
IL261264A (en) 2018-10-31
IL287057A (en) 2021-12-01
AU2013282395A1 (en) 2015-01-29
US20150313972A1 (en) 2015-11-05
US20210317426A1 (en) 2021-10-14
SG11201408761VA (en) 2015-01-29
MY180287A (en) 2020-11-27
AU2016200469B2 (en) 2017-10-12
PH12015502408B1 (en) 2020-02-14
UA129561C2 (uk) 2025-06-04
US11530393B2 (en) 2022-12-20
KR20200143339A (ko) 2020-12-23
PL2867245T3 (pl) 2019-02-28
US9492511B2 (en) 2016-11-15
US20190359958A1 (en) 2019-11-28
IL261264B (en) 2021-10-31
AU2018200230A1 (en) 2018-02-01
BR112014032567A2 (pt) 2017-08-01
CN107596358A (zh) 2018-01-19
HK1249027A1 (zh) 2018-10-26
EA034549B1 (ru) 2020-02-19
PH12014502871A1 (en) 2015-02-23
JP7594365B2 (ja) 2024-12-04
AU2013282395B2 (en) 2015-12-03
EA202090044A1 (ru) 2020-07-31
JP6505629B2 (ja) 2019-04-24
HK1209431A1 (en) 2016-04-01
DOP2014000294A (es) 2015-03-15
WO2014005014A2 (en) 2014-01-03
NZ743910A (en) 2019-12-20
CN107596357A (zh) 2018-01-19
KR20220002227A (ko) 2022-01-06
TR201815811T4 (tr) 2018-11-21
MX2015000190A (es) 2015-04-08
JP2020105209A (ja) 2020-07-09
US20140004096A1 (en) 2014-01-02
JP2015523072A (ja) 2015-08-13
IL236315A0 (en) 2015-02-26
ZA201409397B (en) 2019-10-30
KR20140002451A (ko) 2014-01-08
US10344270B2 (en) 2019-07-09
MX336715B (es) 2016-01-28
JP2016119911A (ja) 2016-07-07
EP2867245A4 (en) 2016-03-09
TWI587869B (zh) 2017-06-21
US20170073652A1 (en) 2017-03-16
CO7240396A2 (es) 2015-04-17
PT2867245T (pt) 2018-11-26
TW201703794A (zh) 2017-02-01
IL287057B1 (en) 2026-01-01
HRP20181897T1 (hr) 2019-01-11
KR20190064542A (ko) 2019-06-10
BR112014032567B1 (pt) 2022-09-13
PH12015502408A1 (en) 2018-03-26
JP6171007B2 (ja) 2017-07-26
CR20140588A (es) 2015-04-06
IL236315A (en) 2016-11-30
EA201492177A1 (ru) 2015-06-30
PE20150720A1 (es) 2015-05-16
CA2877517A1 (en) 2014-01-03
SI2867245T1 (sl) 2018-12-31
CA3008945A1 (en) 2014-01-03
AU2018200230B2 (en) 2020-01-02
HK1249026A1 (zh) 2018-10-26
AU2013282395C1 (en) 2016-03-24
EP2867245B1 (en) 2018-09-12
IL248727A0 (en) 2017-01-31
MX2019008914A (es) 2019-09-26
MX366906B (es) 2019-07-30
EP3441398A1 (en) 2019-02-13
US9051556B2 (en) 2015-06-09
KR20140004603A (ko) 2014-01-13
NZ733366A (en) 2019-12-20
EP2867245A2 (en) 2015-05-06
NZ703093A (en) 2017-08-25
SMT201800612T1 (it) 2019-01-11
MX393364B (es) 2025-03-19
KR101380740B1 (ko) 2014-04-11
PH12020500027A1 (en) 2021-03-15
CY1121519T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
AR091647A1 (es) Purificacion de iduronato-2-sulfatasa
BR112015023447A2 (pt) purificação de proteínas helicoidais triplas
BR112012033703A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
UA100901C2 (ru) Способ очищения фактора свертывания крови viii
IN2012DN00338A (enExample)
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
EA201300054A1 (ru) Полипептид, обладающий активностью бета-глюкозидазы, и его применение
JP2015523072A5 (enExample)
PE20091352A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
EA201201126A1 (ru) Полипептид, обладающий активностью целлобиогидролазы, и его применение
HK1206755A1 (en) Low acidic species compositions and methods for producing and using the same
MX342920B (es) Metodo para purificar polipeptidos o inmunoconjugados activos.
BR112012009227A2 (pt) métodos e sistemas para purificar neurotoxina botulínica não complexada
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
RU2015119517A (ru) Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
WO2012057529A3 (en) Method for purifying human granulocyte-colony stimulating factor from recombinant e. coli
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
WO2010151632A8 (en) Protein purification by caprylic acid (octanoic acid ) precipitation
AR071232A1 (es) Proteina hibrida usada como vacuna contra toxinas shiga de e. coli
PH12015500771A1 (en) Novel fc gamma receptor iib variants
EA201300056A1 (ru) Полипептид с активностью ацетилксиланэстеразы и его применения
BR112012033701A2 (pt) polipeptídeo tendo atividade de degradação de carbohidrato e seus usos
MY171729A (en) Improved harvest operations for recombinant proteins
BR112012033396A2 (pt) Polipetídeo tendo atividade swollenin e seus usos.
EA201590778A1 (ru) ОЧИСТКА КОМБИНИРОВАННОЙ ГАЛАКТОЦЕРЕБРОЗИД-β-ГАЛАКТОЗИДАЗЫ ЧЕЛОВЕКА (rhGALC)

Legal Events

Date Code Title Description
FC Refusal